HEALTHY VOLUNTEERS. FOR PATIENTS WITH AUTISM OR SCHIZOPHRENIA
Conditions
Interventions
Trade Name: Syntocinon nasal Spray
Pharmaceutical Form: Nasal spray
INN or Proposed INN: OXYTOCIN
CAS Number: 50-56-6
Concentration unit: U unit(s)
Concentration type: equal
Concentration number: 40-
Sponsors
UNIVERSITA' DEGLI STUDI DI PARMA
Eligibility
Sex/Gender
Male
Inclusion criteria
Inclusion criteria: Male Caucasian, healthy subjects (age: 18-44 years) with negative history of neurological, medical and psychiatric diseases. Are the trial subjects under 18? no Number of subjects for this age range: 0 F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range 50 F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria
Exclusion criteria: -negative history of neurological, medical and psychiatric diseases - 55 years - women
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Main Objective: Characterize dopaminergic D2 system modulation on prosocial responses to oxytocin;Secondary Objective: Multimodal identification of cerebral responses associated with oxytocin;Primary end point(s): Cerebral and social behavior responses to intranasal oxytocin administration in genetic variants of D2 system;Timepoint(s) of evaluation of this end point: 3 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary end point(s): Cerebral and social behavior responses to intranasal oxytocin administration in genetic variants of D2 system;Timepoint(s) of evaluation of this end point: 3 years | — |
Countries
Italy
Contacts
Public ContactSegreteria Comitato Etico
Segreteria Comitato Etico
Outcome results
None listed